Using 3D echocardiography to assess heart health in mitral regurgitation patients
3D Echocardiography and Cardiovascular PRognosis In Mitral REgurgitation (3D-PRIME)
This study is testing if using 3D heart scans can help doctors better understand and treat people with mitral regurgitation.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 300 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Haukeland University Hospital Academic / other |
| Locations | 1 site (Bergen) |
| Trial ID | NCT04442828 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the effectiveness of 3D echocardiography in improving risk assessment and cardiovascular outcomes for patients suffering from mitral regurgitation. By analyzing various etiologies of mitral regurgitation, the study seeks to determine if advanced imaging techniques can provide better prognostic information. Participants will undergo 3D echocardiographic examinations to assess the severity of their condition and monitor their health over time.
Who should consider this trial
Good fit: Ideal candidates include adult patients with moderate to severe primary or secondary mitral regurgitation who can undergo 3D echocardiographic examinations.
Not a fit: Patients with severe co-existing valve diseases or those unable to provide informed consent may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved risk stratification and management strategies for patients with mitral regurgitation.
How similar studies have performed: While the use of echocardiography is common, the specific application of 3D echocardiography for risk stratification in mitral regurgitation is a novel approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patients with primary or secondary mitral regurgitation (MR) * MR of moderate or severe degree * 3D echocardiographic examinations of \>= good spatial and temporal resolution Exclusion Criteria: * Co-existence of another valve disease of severe degree * Inability to give informed consent
Where this trial is running
Bergen
- Haukeland University Hospital — Bergen, Norway (Recruiting)
Study contacts
- Study coordinator: Dana Cramariuc, MD PhD
- Email: cdan@helse-bergen.no
- Phone: +4755976755
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.